Compounds

US7189816B1 · kind B1 · utility

Assignee

• Active Biotech AB · SE

Inventors

• Thomas Brodin · Ayacucho, PE
• Pia J. Karlström · Lund, SE
• Lennart Ohlsson · Lund, SE
• Jesper Tordsson · Lund, SE
• Philip P. Kearney · Lund, SE
• Bo Nilson · Lund, SE

Key dates

• Filing date: Oct 26, 2000
• Grant date: Mar 13, 2007
• Expiry date: Feb 22, 2021

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/582
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An antibody, or a derivate or a fragment thereof, having a binding structure for a target structure is described. The antibody is displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells. Said binding structure comprises the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23–33 (CDR1), 49–55 (CDR2), 88–98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158–162 (CDR1), 177–193 (CDR2, 226–238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties. There is also described a target structure displayed in, or on the surface of tumour cells, vaccine compositions, pharmaceutical compositions as well as methods related to human malignant diseases.